Study engineer position available in the Cooperative Lab. IGMM and ABIVAX.


The main objectives of the study or research engineer (IE or IR) will be to manage inducible conditional knockout mice and to take part in experiments on mouse inflammation models in order to better understand the mechanism of action of innovative drugs.



– Generate and manage an inducible conditional KO mice:

o     Selection of CREs
o     Breeding and crossing with CRE mice
o     Maintenance of colonies
o     Genotyping
o     Management of the number of animals

– Participate in the induction of inflammatory models: injections (IV, IP, SC and force-feeding), monitoring and weighing of animals and removal of different organs.




 – project management

– significant experience in animal facilities

– experience in KO models and lineage maintenance

– Animal experimentation training with level A (conceptor) mandatory


We are a cooperative Lab CNRS-ABIVAX (public – private) exploring the potential of innovative drugs targeting RNA-binding proteins on inflammation and virus. This is a very exciting project as some of these drugs are already in clinical phases in humans (HIV, ulcerative colitis and rheumatoid arthritis). ABX464, its most advanced compound, was evaluated in Phase II clinical trials and is a first-in-class oral small anti-viral molecule which blocks HIV replication and controls inflammation in ulcerative colitis. While initially selected for its ability to target RNA Binding Proteins (RBPs) involved in viral RNA biogenesis, ABX464 was shown to bind Cap Binding Complex (CBC) involved in splicing and export of human mRNAs. miRNA analysis revealed that ABX464 specifically regulates mir-124 expression, with a significantly increased (about 13 folds). As miR-124 is a modulator of monocyte and macrophage activation, we tested the anti-inflammatory properties of ABX464. ABX464 treatment dampened inflammation in Dextran sulfate sodium (DSS)-induced colitis as well as in Collagen-induced arthritis (CIA), a model of rheumatoid arthritis. A Phase IIa clinical trial to determine its efficacy in patients with Rheumatoid Arthritis is ongoing. We would like to see if the effect of ABX464 depends on the increase in miR-124 using conditional inducible KO mice. The cooperative Lab is composed of 15 peoples with broad and diverse domains of expertise ranging from RNA, chemistry, imaging to immunology. Regular meetings and talks allow everyone to learn and progress.

Expérience :

> 1 year IE or IR

Contact :

Claire DAIEN

Laboratoire coopératif IGMM/ABIVAX, Institut de Génétique Moléculaire de Montpellier, UMR5535-CNRS


offre emploi ABX_IE SA110320

Back to all opportunities